Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Ewen, Margaret ^a   Zweekhorst, Marjolein ^b   Regeer, Barbara ^b   Laing, Richard ^c,d  

^a Vancouver BC   (Netherlands)

^b ATHENA INSTITUTE   (Netherlands)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL DRUG; GENERIC DRUG; DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; NON COMMUNICABLE DISEASE; PRIVATE SECTOR; PUBLIC SECTOR; WORLD HEALTH ORGANIZATION; ECONOMICS; GLOBAL HEALTH; HEALTH CARE DELIVERY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

DRUGS, ESSENTIAL; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HUMANS; PHARMACEUTICAL PREPARATIONS; PRIVATE SECTOR; PUBLIC SECTOR; SURVEYS AND QUESTIONNAIRES; WORLD HEALTH ORGANIZATION;

EID: 85011802377     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0171284     Document Type: Article

References (21)

1. UN General Assembly. Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable diseases. New York: United Nations General Assembly, 2012. Document No. 66/2.
2. WHO website. Q&A's on hypertension, September 2015. http://www.who.int/features/qa/82/en/
3. International Diabetes Federation Diabetes Atlas 6th Edition. Brussels: International Diabetes Federation, 2013.
4. Resolution WHA 66.10. In: Sixty-sixth World Health Assembly, Geneva, 20-27 May 2013. Resolutions and decisions. Geneva: World Health Organization, 2013
5. World Health Organization. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020. Geneva: World Health Organization, 2013.
6. Wagner A, Graves AJ, Reiss SK, LeCates R, Zhang F, Ross-Degnan D. Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. Health Policy 2011 100:151-158. doi: 10.1016/j.healthpol.2010.08.004 PMID: 20828854
7. World Health Organization/Health Action International. Measuring medicine prices, availability, affordability and price components. 2nd edition. Geneva, 2008. http://haiweb.org/what-we-do/priceavailability-affordability/collecting-evidence-on-medicine-prices-availability/
8. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. 17 Jan 2009 Lancet 373:240-249. doi: 10.1016/S0140-6736(08)61762-6 PMID: 19042012
9. Van Mourik MSM, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord 2010, 10:25. doi: 10.1186/1471-2261-10-25 PMID: 20534118
10. Cameron A, Bansal A, Dua T, Hill S, Moshe S, Mantel-Teeuwisse A, et al. Mapping the availability, price and affordability of antiepileptic drugs in 46 countries. Epilepsia 2012 Jun; 53(6):962-9. doi: 10. 1111/j.1528-1167.2012.03446.x PMID: 22432967
11. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability. An international comparison of chronic disease medicines. WHO EMRO/HAI 2006.
12. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr., Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull of the World Health Organ 2007 85(4):279-287.
13. Prices, availability, affordability and price components of medicines to treat non-communicable diseases in Lebanon. World Bank/WHO EMRO/HAI, 2013. http://haiweb.org/survey-related-reports/ (accessed 4 February 2015)
14. Prices and affordability of medicines to treat non-communicable diseases in Egypt. World Bank/WHO EMRO/HAI, 2013 http://haiweb.org/survey-related-reports/ (accessed 4 February 2015)
15. Niëns LM, Van de Poel E, Cameron A, Ewen M, Laing R and Brouwer WBF. Practical measurement of affordability: an application to medicines. Bull of the World Health Organ 2012 90:219-227.
16. Volman B. Direct costs and availability of diabetes medicines in low- and middle-income countries. WHO/HAI 2008. http://haiweb.org/pricing-publications/ (accessed 4 February 2015)
17. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HGM, Laing RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull of the World Health Organ 2011 89(6):279-287.
18. WHO/HAI medicine price and availability database. http://haiweb.org/what-we-do/price-availabilityaffordability/price-availability-data/ (accessed 3 January 2015)
19. WHO/HAI 2011. Review series on pharmaceutical pricing policies and interventions. http://haiweb.org/ what-we-do/price-availability-affordability/resources-for-pricing-policies/ (accessed 20 May 2015)
20. WHO 2015. Guideline on country pharmaceutical pricing policies. http://www.who.int/medicines/ publications/pharm-guide-country-price-policy/en/ (accessed 20 May 2015).
21. Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Selvaraj S, Kiddell-Monroe R, et al. on behalf of The Lancet NCD Action Group. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. The Lancet 2013 Feb 23; 381(9867):680-9.